Jubilant Pharmova has appointed Daniel J O'Connor as the CEO of its novel drugs business. O'Connor brings over 30 years of leadership experience in biotechnology and oncology. His expertise includes creating value around differentiated, IP-rich platforms. Previously, he was CEO of Ambrx Biopharma, where his leadership led to a significant increase in company valuation and its successful acquisition.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9ITnu4N
via IFTTT
No comments:
Post a Comment